Home › Funds › Novo Holdings A/S › XENE
Novo Holdings A/S position in XENE
XENON PHARMACEUTICALS INC · Health Care
Novo Holdings A/S reported holding 652,105 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$24.3M, representing 1.63% of its reported portfolio and ranking #18 among its reported holdings. Novo Holdings A/S has disclosed XENE holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Novo Holdings A/S's XENE position evolved
Novo Holdings A/S first disclosed a stake in XENE in Q1 2026 at 485,438 shares (US$28.2M). The position peaked in Q2 2026 at 485,438 shares, worth US$29.3M. Across 3 filings, Novo Holdings A/S increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 652,105 shares valued at US$24.3M — an increase of 166,667 shares quarter over quarter.. Notable position changes include a 34% increase in Q3 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 485.44K | $28.23M | New |
| Q2 2026 | 485.44K | $29.30M | Hold |
| Q3 2026 | 652.11K | $24.25M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 26 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$204.5M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$132.3M), Affinity Asset Advisors, LLC (US$70.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.50M sh · $204.54M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 3.56M sh · $132.31M · Q3 2026
- Affinity Asset Advisors, LLC 1.90M sh · $70.67M · Q3 2026
- BRAIDWELL LP 1.71M sh · $63.54M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $60.09M · Q3 2026
- ADAR1 Capital Management, LLC 1.16M sh · $43.22M · Q3 2026
More on Novo Holdings A/S
FAQ
How long has Novo Holdings A/S held XENE?
Novo Holdings A/S has disclosed XENE holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Novo Holdings A/S's current position in XENE?
As of Q3 2026, Novo Holdings A/S holds 652.11K shares of XENE (XENON PHARMACEUTICALS INC), valued at $24.25M, representing 1.63% of its reported portfolio and ranking #18.
Has Novo Holdings A/S been buying or selling XENE?
In the latest 13F filing (Q3 2026), Novo Holdings A/S increased its position in XENE. The position peaked in Q2 2026 at 485.44K shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, Affinity Asset Advisors, LLC, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.